Autism Disorder and Treatment Market 2019 Global Players as Pfizer, Allergan, Merck & CO Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson Services, etc

Market Research Future (MRFR)’s latest Report Projects that the Global Autism Disorder and Treatment Market is set to Register a CAGR of 4.37% during the forecast period 2019 to 2023. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Autism Disorder and Treatment Market - Synopsis

As per Market Research Future (MRFR)’s analysis, the global autism disorder and treatment market is expected to mark a CAGR of 4.37% during the forecast period 2017 to 2023. Autism is a developmental disorder which is characterized by communication challenges, repetitive behavior, etc. In 2015, estimation of the global autistic population had reached 24.8 million. The count has been projected to further increase in the upcoming years. This, in turn, is likely to have a positive influence on the growth of the autism disorder and treatment market.

Although no cure has been found, a number of treatments such as behavioral therapy, speech therapy, etc. are developed for the patients. Furthermore, research & development activities are being incessantly undertaken for the development of the treatments available in the market. The development of autism culture has intensified the demand for a cure and the acceptance of autism as a difference rather than disorder has raised awareness about the same. It is likely to favor the expansion of the autism disorder and treatment market in the forthcoming years. However, a weaker pipeline for drugs is expected to hinder the growth of the market over the next couple of years.

Request Sample Copy at https://www.marketresearchfuture.com/sample_request/1605

Competitive Dashboard:

Some of the key players profiled in the report are Pfizer Inc., Allergan, Merck & CO Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson Services, Inc. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Consern Pharma Private Limited, Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., and Saniona AB.

Industry News:

In January 2019, a bill has been advanced in Colorado for legalizing the use of marijuana for the treatment of autism.

In January 2019, a group of researchers in Japan, led by Professor Hidenori Yamasue of Hamamatsu University School of Medicine, is conducting a clinical trial to make available for use as a nasal spray a drug that improves symptoms of autism spectrum disorder, or ASD.

In January 2019, Neurochlore, a French biotechnology company, and Servier, an international pharmaceutical company, has announced the launch of phase 3 studies in Europe to evaluate the use of bumetanide for treating children who have autism.

Market Segmentation:

By type, the global autism disorder and treatment market has been segmented into Asperger Syndrome, Pervasive Developmental Disorder, and others.

By treatment type, the autism disorder and treatment market have been segmented into ABA (applied behavioral analysis), hyperbaric oxygen therapy, chelation therapy, oxytocin therapy, and others.

By drug, the global autism disorder and treatment market is segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. The anti-psychotic segment is further sub-segmented into Abilify (aripiprazole) and Risperidone.

Regional Analysis:

By region, the global autism disorder and treatment market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas has witnessed an upsurge in demand for autism screening tests owing to the rising awareness about its availability and access. It is expected to emerge as the largest regional autism disorder and treatment market globally in the foreseeable future. In addition, the approval and expected launch of the atypical anti-psychotic in the U.S. such as Namenda and Latuda is poised to catapult the sales of the market across the review period.

Asia Pacific houses a significant proportion of the autistic population. The developments in the healthcare sector of the region have created an awareness among the people for screening and treating autism. This, in turn, is prognosticated to have a favorable impact on the growth of the autism disorder and treatment market in the forthcoming years. It is projected to thrive at a relatively higher CAGR over the assessment period. Meanwhile, the Middle East & Africa is likely to hold a small share of the autism disorder and treatment market and exhibit steady growth through the projection period.

Browse Complete 108 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at

https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.